The leadership of Rite Foods Limited in the manufacturing of snacks has been reaffirmed, as the company emerges the winner of ECOWAS Sausage Roll Snack Manufacturing Company of the Year.
The Rite Foods sausage brands which comprise the Bigi Beef Sausage Rolls, Rite Spicy Beef Rolls and Rite Sausage Rolls beat other sausage brands and snack manufacturing companies in the West African sub-region to clinch the award, held in Lagos, Nigeria.
The award was bestowed on the company for being a major player in the sausage segment of the food industry and for undisputedly taking the lead in sausage innovation amongst the industry players in the ECOWAS sub-region, manufacturing under high ethical standards and hygienic conditions to produce quality snacks that are fit for consumption.
Receiving the award on behalf of the company, Olumide Aruleba, Head of Marketing, Rite Foods Limited stated that the company’s commitment to its core values of innovation and excellence has bolstered its efforts of operating on global standards in the ECOWAS region and continent.
“Innovation and excellence are our core values at Rite Foods Ltd which helps us to remain committed to operating on global standards to meet the needs of consumers across the West-African region and continent”, Aruleba stated.
He further affirmed that the consumer-centric company has its customers at the core of its mission, hence its range of products caters to the needs of different consumers in different regions of the continent and the globe. He also expressed the company’s appreciation to the organizers of the award for the recognition and award.
The ECOWAS Manufacturing Excellence Award recognizes, rewards and celebrates the efforts of individuals, corporate leaders and organizations who have contributed immensely to the socio-economic growth of the ECOWAS sub-region and African continent, despite the global economic challenges in the post-pandemic era.
Rite Foods Limited is a truly world-class and proudly Nigerian Foods and Beverages manufacturing company which began food production in March 2008. It boasts of a wide range of brands like the Bigi soft drink with thirteen flavors, Fearless energy drink with two flavors, Sosa fruit drink with five flavors as well as the award-winning Bigi and Rite Sausages, which are well-known staple delicious sausage rolls in Nigeria that fuels and recharges consumers across the continent and produced with state-of-the-art infrastructure and up-to-the-minute technology located in Ososa, Ogun state, Nigeria.
At the start of August, Jobberman, Nigeria’s foremost recruitment company hosted a webinar that brought together top HR professionals and senior-level executives with first-hand knowledge of the positive impacts that internship and entry-level graduate programs can have on businesses.
The purpose of the webinar was to encourage organizations at all levels to see internships and entry-level positions as a low-cost training ground for skill development, despite the perceived element of risk.
Enticed by bumper work incentives by firms abroad, Nigerian tech talents, for instance, that are either leaving or taking on remote roles, are causing their local employers to have sleepless nights and forcing them to rethink their recruitment approach. This puts local firms in direct competition with global firms for talent, and there is a need to be more flexible in their offers as the allure of remote work and the gig economy deepen the search for qualified mid to senior-level talent.
The webinar, which was titled “Harnessing The Business Benefits of Internship Programs,” featured top HR professionals from Jobberman, TGI Group, and a former McKinsey and Company consultant, who shared tips on managing the recruitment process to suit business goals, increasing talent retention, and managing business expectations as the panellists attempted to demystify the challenges to entry-level employment that most job seekers face, as well as how businesses may make the most of internships and entry-level roles without becoming a corporate training ground.
The discussion session was led by Bukola Okikiolu, the Communications Specialist at Jobberman Nigeria. Other panellists include Chisom Ofili, Head of Recruitment at Jobberman Nigeria; Abimbola Osibodu, an ex-recruitment specialist at McKinsey & Co.; and Kehinde Alo, Head, Learning & Development at TGI Group.
Jobseekers tend to look for new possibilities when they have been adequately armed with the necessary skills to earn more in their professions, which is why most firms are seldom unwilling to recruit interns or job seekers with little or no relevant experience. But the answer to this isn’t outright ignoring them. Kehinde suggests that training can be designed around significant business concerns with predetermined ROIs so that if the candidate quits, the host organization will have profited from the relatively brief connection and relevant business challenges could have been attended to within that time frame.
According to Abimbola, one possible solution to employee retention is to provide interns and other employees with a clear route to professional advancement. She observed that the majority of people who advance to management roles at the most desirable consulting companies begin as junior associates or interns who are adequately supported by more senior staff members.
When workers began quitting their jobs in droves in early 2021, analysts assumed that the “Great Resignation” was a direct result of pandemic turmoil and uncertainty. Many employees left because their employers could not give appropriate remote-work assistance. A lot more have departed, seeking greater autonomy. Many others left for better pay elsewhere when the labour market tightened. Even though COVID restrictions have mainly been relaxed, resignation letters continue to pile up. Panellists suggest that a poor work culture could be responsible for this.
Chisom observes that enthusiasm for completing things and a good outlook are contagious. It immediately spreads and demonstrates how productive and content everyone is at work when individuals smile, communicate cordially with one another, and crack jokes. Businesses should foster a positive work environment so that new employees feel empowered to speak out, have their opinions acknowledged, and be a valuable part of the team.
As part of their commitment to encouraging businesses to hire more interns, Jobberman is providing employers with a free listing of internship and entry-level positions requiring no more than three years of experience. This, however, is consistent with their aim of matching excellent employees with quality talent.
HANOI, VIETNAM – Media OutReach – 29 August 2022 – VinAI – a member company in Vingroup’s tech ecosystem and VinFast’s strategic partner – is one of the world’s top 20 Artificial Intelligence research-based companies whose mission is to bring state-of-the-art research into real-life impact.
LOS ANGELES, US – Media OutReach – 29 August 2022 – BitDD.co, a US-certified crypto exchange is bringing greater confidence, trust and credibility to the industry, where over 80% of trading platforms have no certification, and amid the current volatility in the crypto world.
SHENZHEN, CHINA – Media OutReach – 29 August 2022 – OPPO today announced the ten winners of the inaugural OPPO Research Institute Innovation Accelerator. The OPPO Research Institute Innovation Accelerator has seen teams from around the world submit technology proposals aimed at tackling some of society’s biggest challenges. Following a three-month submission and judging process, the ten winning teams will share the RMB 3,000,000 (USD $460,000) prize fund and other resources provided by OPPO and its partners.
Levin Liu, OPPO Vice President and President of the OPPO Research Institute
“Over the past few months, we have seen hugely innovative solutions that leverage the power of science and technology to address some of the biggest issues facing society right now,” said Levin Liu, OPPO Vice President and President of OPPO Research Institute. “As we continue to explore and push the boundaries of technology, we do so in alignment with our mission of ‘Technology for Mankind, Kindness for the World’. Through technological innovation, we want to help society develop in a positive direction and bring the benefits of Virtuous Innovation to more people. In the future, we look forward to working with more innovators to tackle key problems like these through the OPPO Research Institute Innovation Accelerator.”
With today’s most pressing challenges too big for any individual organization to tackle alone, OPPO established the OPPO Research Institute Innovation Accelerator to discover and develop technology that could help benefit those most in need of it. Following the announcement of the winners of this year’s Innovation Accelerator, OPPO will help the ten teams to further develop and promote their technologies by providing financial support, marketing resources, opportunities to apply their concepts in OPPO products, and exhibition of their ideas at global events.
Over the years, OPPO has built up vast experience in the areas of accessible technology and digital health, leveraging its understanding of user needs and insights to create tailored solutions for specific groups of users. For example, the OPPO Find X3 series includes a Color Vision Enhancement feature designed to improve the visual experience for those with color vision deficiencies. OPPO has also brought aging adaptation to its ColorOS operating system and smart products to enable elderly users to enjoy the benefits and convenience of technology. Further to this, OPPO has established the OPPO Health Lab to develop preventative health solutions designed to help users develop healthy lifestyle habits. In the future, OPPO will continue to develop its own technology and work with innovators worldwide to bring the benefits of technology to more people.
Pinup® and Boshutai® Generated Remarkable Turnover while Achieving Record High ProfitAim to Build a Highly Commercial-Driven and Specialized R&D Platform
HONG KONG SAR – EQS Newswire – 29 August 2022 – A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (“Uni-Bio Science”, together with its subsidiaries referred to as the “Group”, stock code: 0690.HK), is pleased to announce its interim results for six months ended 30 June 2022 (the “Period”), as well as its comparative figures for six months ended 30 June 2021.
Key Accomplishments in the First Half of 2022
During the Period, the Group achieved a spectrum of accomplishments, for both of its marketed products and innovative biologics. The key highlights include:
1. During the Period, the Group’s recorded a turnover of approximately HK$195.6 million, representing a noticeable increase of 24.6% year-on-year (“YoY”). Sales of Pinup® and Boshutai® registered significant increase of 75.6% YoY and 410.2% YoY respectively.
2. The Group achieved a record high profit for the Period of approximately HK$14.6 million with a significant increase of 663.6% YoY. The profit was solely from its core operations and organic growth.
3. During the Period, the clinical work of Uni-GLP-1 injection pen was being accelerated. The Group also in preparation to the development of oral form Uni-GLP-1 to expand the value of the product and offer convenience to users.
4. The Group launched its new research center in Hong Kong and upgrade its business model to a “four-wheel drive” model, which included high-value generic drugs, bio-innovative drugs, CMO business and the newly introduced, advanced skincare raw materials. The Group has been building a highly commercial-driven and specialized boutique R&D platform, tightly integrating research and production under one roof.
5. During the Period, the marketing application of Bogutai® (teriparatide injection) was accepted by the China National Medical Products Administration (“NMPA”). Bogutai® is the Group’s fifth marketed drug and it is also the first domestic manufactured PTH Liquid in China to use a disposable injection pen. The Group strongly believes that Bogutai® will be a future blockbuster for the Group by virtue of the product’s strong cost advantage, better therapeutic effect and convenient administration method.
6. The Group’s Acarbose Tablets (Boshutai®) was successfully selected for Henan Thirteen Provinces Alliance Procurement with procurement validity period set at 2 years. This marked another milestone for the Company and has given the Group an opportunity to quickly expand the in-hospital market share. To satisfy the massive demand for Boshutai® going forward, the Group has already expanded its production capacity in its partner Suzhou production site to ensure its supply stability.
Interim Results
During the Period, the Group recorded a turnover of approximately HK$195.6 million, representing a significant increase of 24.6% year-on-year (first half of 2021: HK$157.0 million). The increase in turnover was mainly attributable to the remarkable sales growth of Pinup® and Boshutai®. Pinup® recorded a noticeable increase of 75.6% in turnover from approximately HK$56.1 million to approximately HK$98.5 million during the Period. The increase was attributable to Pinup®’s inclusion in the national centralized procurement in 2021, which has secured the Group with massive hospital orders. Turnover of Boshutai® increased substantially from approximately HK$1.3 million to approximately HK$6.5 million, representing a significant increase of 410.2%. GeneSoft® recorded an increase in turnover from approximately HK$17.2 million to approximately HK$17.8 million, representing an increase of 3.1%. Turnover generated from GeneTime® was approximately HK$72.7 million, representing a decrease of 11.7% from approximately HK$82.4 million in the first half of 2021. The production of GeneTime® was interrupted in the first quarter of 2022 due to the pandemic prevention and control measures implemented by the local government, resulting in the decrease of sales volume.
Gross profit was approximately HK$144.5 million, representing an increase of 16.1% as compared with approximately HK$124.4 million for the first half 2021, whereas gross profit margin was 73.9% (first half of 2021: 79.3%). The Group continued its strict control in general and administrative expenses, which only accounted for 12.1% of turnover for the Period as compared with 14.2% for the same period last year. The selling and distribution expense for the Period also decreased to 43.5% of turnover from 48.5% that of the same period last year partly due to the direct sales of GeneSoft® started with the Group’s self-developed, stable and efficient sales team since the second half of 2021. The Group’s sales team has greatly enhanced the distribution channel, promotion capability and efficiency of GeneSoft®. The R&D expenses increased by 13.8% to approximately HK$24.3 million as the Group continued to be research- and innovation-focused.
The Group recorded earnings before interest, tax, depreciation and amortization (“EBITDA”) for the Period of HK$27.6 million as compared to HK$13.1 million of the same period last year. Other revenue for the Period surged by 6,351.7% to approximately HK$5.6 million, which was mainly attributable to its growing CMO business. Despite of the Group’s continuous investment in R&D, its cash flow from operating activities for the Period remained positive. This reflects the Group’s strong capability to generate its own capital and support its major investments. The Group recorded a profit of approximately HK$14.6 million for the Period, representing a dramatically increase of 663.6% year-on-year (first half of 2021: HK$1.9 million). The increase in profit was mainly attributable to the impressive sales growth of GeneSoft®, Pinup® and Boshutai®, the increase in CMO business as well as the effective control of operating expenses. Basic earnings per share was approximately HK$ 0.23 cents (first half of 2021: HK$0.03 cents).
Prospects
China has introduced various regulatory reforms to promote the R&D development in the healthcare and biopharmaceutical sector. To ride on the favorable policies and capture the growing market opportunity, the Group has officially upgraded its business model to a “four-wheel drive” model, which includes high-value generic drugs, bio-innovative drugs, advanced skincare raw materials and CMO business, especially focusing on diabetes, ophthalmology, orthopedics and other therapeutic areas. With a new R&D centre set up in Hong Kong Science Park, the Group will be able to develop new innovative bio-products more quickly and efficiently, expand its product portfolio and reshape its R&D system, thus opening up new room for strategic growth.
Looking forward, Mr. Kingsley Leung, Chairman of Uni-Bio Science said, “We will adhere to our ‘strong R&D’ direction and continuously cultivate our internal strength. We have established short-to-long term goals to promote sustainable growth. In short term, our existing product lines will come to fruition. We expect our star products, GeneTime® and GeneSoft®, together with our two high-value generic drugs, Boshutai® and Pinup®, which have both successfully selected for centralized procurement, will continue to bring fast growing income to the Group. Besides the matured products, we will continue to explore the advanced skincare raw materials market. Leveraging our partner, Global Cosmetics’ extensive experience in the skincare industry, we have been working together on 5 functional raw materials, including collagen, fibronectin, beauty peptides, probiotics and exosomes. It’s also worth mentioning that the market application of Bogutai® (teriparatide injection) has been accepted by the NMPA in June 2022, meaning Bogutai® is likely to be the Group’s fifth marketed and self-developed drug. We believe that the launch of Bogutai® and advanced skincare raw materials will diversify our revenue stream, allowing us to enhance our profitability whilst decreasing our business risk going forward.
In medium term, we will diversify the outreach of EGF products while broadening ophthalmology products offerings. We would like to further extend the product life span of EGF products and develop different dosage forms of GeneTime® in order to bring greater convenience for our clients. In addition, we are planning to kick off the development of single dose form of GeneSoft® (no preservatives) utilizing a new Blowing Filling and Sealing (“BFS”) packaging technology, which will be safer and more convenient to use. The BFS packaging technology will also be used to produce Diquafosol Sodium Eye Drops, which is complementary to GeneSoft® and can generate synergy in sales.
In long term, we will continue to leverage the Group’s advanced scientific research technology, together with the innovative capabilities of our technology partners, we will continue to enhance our comprehensive R&D strength, diversifying our best-in-class drug portfolio while expanding business scope beyond. We will continue to actively expand the R&D channels, carry out multi-level R&D cooperations with different institutes to develop innovative biologic formulation technology, such as oral-peptide technology and CEPP, and explore new drug candidates using new antibody modalities. We particularly excited about the prospects of the oral GLP-1 and will accelerate the R&D progress, targeting to launch the product in the near future.”
Hashtag: #Uni-BioScience
About Uni-Bio Science Group Limited
Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The research and development centre is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with NMPA requirements. The Group also has two GMP manufacturing bases in Beijing and Shenzhen. The Group also has a highly efficient commercialization platform and marketing network. The Group focuses on the development of novel treatments and innovative drugs addressing the therapeutic areas of endocrine such as diabetes and osteoporosis, ophthalmology and dermatology.
Uni-Bio Science Group Limited was listed on the Main Board of the Hong Kong Stock Exchange on November 12, 2001. Stock code: 0690.
New SonicWave 600 Series wireless access points, with Wi-Fi 6 technology, deliver always-on, always-secure connectivity for the most complex environments
SINGAPORE – Media OutReach – 29 August 2022 – SonicWall today announced the introduction of the new Wi-Fi 6 wireless security product line, which provides always-on, always-secure connectivity for complex, multi-device environments. Powered by Wi-Fi 6 technology, the new SonicWave 600 series wireless access points, coupled with Wireless Network Manager (WNM) 4.0, enable organizations to automatically secure wireless traffic while boosting performance and simplifying connectivity.
“In today’s hyper-connected world, organizations of all sizes are scaling high-performance wireless networks that need to be simple to deploy, dependable and secure,” said SonicWall President and CEO Bob VanKirk. “The SonicWave 600 series gives our global partner community and strategic MSSPs another solution to help protect their customers with secure, easy-to-manage wireless connectivity for the complex environments where they do business.”
SonicWall Wireless Network Manager (WNM) 4.0 provides an easy, effective way for enterprises, partners and MSSPs to securely manage wireless networks. WNM leverages the cloud to simplify management of complex environments with a unified, single-pane-of-glass cloud management portal.
The SonicWave 600 series uses Wi-Fi 6 technology which can increase overall wireless throughput by up to 4X compared to Wi-Fi 5 technology and reduce latency by up to 75%. Additionally, the SonicWave 600 series includes key features that address business needs for security, management, ease of deployment and scalability, including:
Increased wireless throughput by up to 4X. Superior Wi-Fi 6 performance using 802.11ax technology improves throughput, latency and total cost of ownership (TCO).
Ultra-fast wireless speeds on busy networks. Powered by Wi-Fi 6 technology, the SonicWave 600 series helps eliminate issues arising from crowded wireless networks while ensuring top speeds in highly dynamic environments.
Advanced cyberattack prevention. Increase confidence and block advanced cyberattacks with wireless access points integrated with the award-winning SonicWall Capture Advanced Threat Protection (ATP) sandbox service, patented Real-Time Deep Memory Inspection (RTDMI) and Reassembly-Free Deep Packet Inspection.
Threat detection and removal. Scan all wireless traffic coming into and going out of the network using deep packet inspection technology, and then remove harmful threats such as malware and intrusions, even over SSL/TLS-encrypted connections.
Reduced downtime. Never let a dropped or disrupted connection impact business, and safeguard revenue channels with secure, always-on connectivity for distributed networks.
Ability to build an optimized IoT environment. Design and scale high-performance networks capable of connecting dense, multi-device environments.
Upgrades along the way. Ensure consistency while improving performance and security by upgrading your environment — at your speed and within budget — to the latest technology that is fully backward-compatible.
“SonicWall has consistently provided solutions that have helped keep our campus secure over the years,” said Pam Messex, Chief Information Officer at Berean Baptist Church & Academy. “Educational environments have the challenge of being both secure and open simultaneously. Students need easy access to various resources, while staff members need to maintain secure records and safeguard personal information. Adding SonicWave wireless access points to our network gives us the ability to do this. We have come to rely on features such as segregation and security through client isolation, ease of use, and performance — especially as our campus becomes increasingly wireless.”
All SonicWave access points, including the new SonicWave 600 series, integrate with the cloud-delivered Wireless Network Manager 4.0, which allows for control and troubleshooting of wireless and switching access across networks of any size or region with a single pane of glass.
Designed with MSSPs in mind, the Wireless Network Manager infrastructure simplifies access, control and troubleshooting by unifying multiple tenants, locations and zones, while supporting thousands of SonicWave access points and SonicWall network switches — all without the cost of complex overlay management systems.
“The threat landscape evolves far too quickly to rely on legacy solutions,” said SonicWall Vice President of Products Jayant Thakre. “This advanced offering places additional emphasis on extending the performance of wireless networks with real-time threat mitigation. Businesses and their end users expect the best in real-time security, performance and analytics — regardless of the type of network or physical location.”
Debasish Mukherjee, Vice President, Regional Sales, Asia Pacific Japan at SonicWall added, “In today’s fast paced and increasingly connected world we live in, it’s only imperative that our environment remains secure yet open to new advancements. With the new SonicWave 600 series that uses Wi-Fi 6 technology, we can deliver always-on and always-secure connectivity even for the most complex environments. This means that end users can expect the best in real-time security, performance and analytics — to facilitate the management, ease of deployment and scalability of their operations regardless of the network or physical location they are in.”
The SonicWave 600 series will also be expanded with the release of SonicWave 621, currently scheduled for release by the end of calendar 2022.
SonicWall delivers Boundless Cybersecurity for the hyper-distributed era in a work reality where everyone is remote, mobile and unsecure. SonicWall safeguards organizations mobilizing for their new business normal with seamless protection that stops the most evasive cyberattacks across boundless exposure points and increasingly remote, mobile and cloud-enabled workforces. By knowing the unknown, providing real-time visibility and enabling breakthrough economics, SonicWall closes the cybersecurity business gap for enterprises, governments and SMBs worldwide. For more information, visit www.sonicwall.com or follow us on Twitter, LinkedIn, Facebook and Instagram.
Net profit HK$570 million; Interim dividend HK$0.06/share Seize development opportunities; Enhance competitive strength
Result summary:
Total revenue HK$3,405 million, representing a growth of 39.4%;
Net profit HK$570 million, representing a growth of 106.8%;
The Board resolved to pay interim dividend of HK$0.06 /share
HONG KONG SAR – Media OutReach – 29 August 2022 – SSY Group Limited (“SSY” or the “Company”; Stock Code: 2005.HK) and its subsidiaries (together, the “Group”) presents the interim results of the Company for the six months ended 30 June 2022.
During the first half of 2022, the Group achieved a revenue of HK$3,405 million, representing an increase of 39.4% compared to corresponding period of last year (“1H2021”) with gross profit margin 57.0%, representing a decrease of 3.2 percentage points compared to 1H2021. The Group achieved a net profit of HK$570 million, representing an increase of 106.8% compared to 1H2021.
Faced with pressure from continuous impacts of the epidemic, shrinking market demands and supply shock, the Group seized the development opportunities arising from changes in the industrial landscape and policy support, and implemented a series of measures to improve quality and enhance efficiency of its main business segments including preparations, bulk pharmaceuticals and medical materials, so as to maintain good growth momentum. Focusing on the dual circulation of domestic and international markets development pattern, the Group concentrated its efforts on market development for dominant preparations and key types of preparation products, and explored the domestic and overseas markets for its bulk pharmaceuticals and medical materials products. The Group also proactively optimised its product mix and placed great emphasis on the marketing of new featured products, leading to a new growth in market shares and sales volume.
The Board of directors proposed to pay an interim dividend of HK$0.06 per share for year 2022, which increased by 20% as compared to 1H2021. The total amount of interim dividend this year to be paid is approximately HK$179 million.
Amidst the normality under epidemic, the domestic pharmaceutical market witnessed a stable rigid demand. The Group continued to increase the market shares of the intravenous infusion solution and continuously solidified its leading position in the market. During the first half year, the sales volume of infusion solutions reached 754 million bottles (bags), representing an increase of 19.3% compared to 1H2021. Revenue of infusion solutions reached HK$1,834 million, representing an increase of 20% compared to 1H2021. Ampoule products delivered a remarkable market performance and have become a new support for the development of the Group’s injection segment. During the first half year, the revenue of ampoule products was HK$511 million, representing an increase of 4.7% compared to 1H2021, which maintained a good growth momentum. Solid preparations business segment delivered a steady and positive sales performance. In line with the national and local centralised procurement policies, the Group made coordinated efforts to secure market supply of tender-awarded products to promote and expand the market of new products. During the first half year, the revenue reached HK$145 million, representing an increase of 71% compared to 1H2021. Bulk pharmaceuticals business achieved a boost in both production and sales. After continuous optimization of production process, the premium production capacities were realised rapidly. In particular, as a vertical integration, the Group acquired Cangzhou Lingang Youyi Chemical Co., Ltd. at the beginning of the year, significantly improving the coordination between upstream and downstream entities of the industrial chain. During the first half of the year, revenue of bulk pharmaceuticals reached HK$777 million, representing an increase of 214.6% as compared to 1H2021. The Group achieved a growth jump in production and sale of medical materials. In the first half of the year, revenue from external customers of the Group recorded HK$90.55 million, representing an increase of 12.5% compared to 1H2021.
By using market demands as the guide and adhering to the strategy of “combination of generic and innovative drugs”, the Group made continuous and coordinated efforts to push forward the research and development of featured generic drugs, bulk pharmaceuticals, innovative drugs, medical materials as well as product types under consistency evaluation. The Group kept solidifying and expanding its strength in the research and development of featured generic drugs. During the first half of the year, a total of 22 production approvals were obtained, including 14 types of infusion products and 8 types of bulk pharmaceuticals, with the number of approvals obtained exceeding that of the whole year of 2021. So far, a total of 26 product types with 35 specifications of the Group have passed or were regarded as passing the national consistency evaluations regarding the quality and efficacy of generic drugs. During the period, 124 products of various types were also submitted by the Group to the Center for Drug Evaluation of the National Medical Products Administration for approval, including 100 preparation products (including products for consistency evaluation) and 24 types of bulk pharmaceuticals. The Group achieved positive progress in the Phase 1 clinical trial of the Type I innovative drug NP-01 project, and were stepping up efforts in the preparation of application materials for Phase 1 clinical trial for the innovative drug including ADN- 9, aiming to apply within the year. In addition, the bioprocessing film project of Jiangsu Best New Medical Material Co. Ltd. with an annual production capacity of 20 million square meters has completed construction and was ready for production on July 2022, providing a solid foundation for overall improvement of market supply capacity.
Looking forward to the second half of 2022, economic situation may remain severe and complicated amidst the normality under global epidemic. The Group will actively seize development opportunities and will make effort to facilitate the dual circulation of domestic and international markets in order to secure preemptive opportunities for development. On the preparations business, the Group will have an in-depth and a better systematic analysis on national and local centralized procurement policies, and will seize the market opportunities arising from the eighth round of National Centralised Medicines Procurement, with an aim to expand the market share and influence of its products passing the consistency evaluation. On the bulk pharmaceuticals business, the Group will proactively facilitate the domestic and international markets, and make efforts to strengthen and expand its bulk pharmaceuticals business, aiming to make a greater contribution to the development of the Group. In terms of research and development, the research and development of specialised generic drugs remains the focus of the Group’s research and development work for the moment. Facing the increasingly intensified competition in the research and development of generic drugs, the Company will leverage on the cooperation mechanism with universities and scientific research institutes, and explore more high quality research projects. The Group will continue to push forward proactively the spinoff listing of bulk pharmaceuticals segment in the PRC. At the same time, the Group will proactively seek opportunities of acquisition and investment in the pharmaceutical industry in order to increase the return on investment.
Mr. Qu Jiguang, Chairman and CEO of SSY said, “Facing the risks and challenges in the post-pandemic era, the Group will seize new opportunities for development in the industry. We will maintain the resilience and vitality of innovative development, and strive for facilitating the quality development of the Group. We firmly believe that, by virtue of the scale, quality, management and brand advantages accumulated in the industry over the years and the continuous innovation momentum released by the Group, we will strive to create new high record again in year 2022 in terms of production, sales and profit, and will bring satisfactory returns to our investors with a stronger result of development.”
Hashtag: #SSY
The issuer is solely responsible for the content of this announcement.
About SSY Group Limited
SSY Group Limited is one of the leading pharmaceutical manufacturers in China with nearly 7 decades of operation history and a well-established brand name. The Group went public on the Hong Kong Stock Exchange in December 2005 with stock code 2005. The Group is principally engaged in the research, development, manufacturing and selling of a wide range of pharmaceutical products, including finished medicines of mainly intravenous infusion solution and ampoule injection to hospitals and distributors, bulk pharmaceuticals and medical materials. The manufacturing plants of the Group locates in Hebei Province and Jiangsu Province in China, and its pharmaceutical products has leading position in the high-end hospital market in China.
60% of Malaysian Consumers Buy Local Ahead of Merdeka Day
KUALA LUMPUR, MALAYSIA – Media OutReach – 29 August 2022 – 60% of Malaysian consumers are proactively supporting local sellers ahead of Merdeka Day with #ShopeeSapotLokal, at the live reveal of the platform’s largest marketplace study this year, Celebrating the Heart of Malaysia on E-Commerce*, ahead of the company’s 9.9 Super Shopping Day.
“Interestingly, not all buyers prioritise discounts and vouchers exclusively. Seven in 10 Malaysians value peace of mind over lower price,” according to Kenneth Soh, Head of Marketing Campaigns at Shopee Malaysia.
Nine in 10 Malaysians still buy online despite the reopening of physical outlets because it is a learned and adopted habit. The majority value having ‘peace of mind’, with 40% enjoying the convenience of parcels delivered to their doorstep, 17% feeling safe with Shopee Guarantee, and 10% trusting reviews and pictures from other buyers.
For 49% of buyers, Shopee is the top-of-mind shopping destination for lifestyle products, including home decoration items, fashion pieces, and health and beauty products. Apart from that, 24% of buyers purchase living essentials (groceries and diapers) from Shopee, 16% look for tech devices (computers, mobile devices and TV) and the remaining 11% buy automobile parts or work and school supplies.
“When Malaysian consumers express their values through online shopping preferences this way, we truly understand why eight in 10 local sellers started their selling journey online with Shopee. We are humbled to discover that half of our local sellers surveyed say the income earned on our platform is crucial as it enables them to support their families,” said Soh.
The majority of local sellers began selling online with Shopee to overcome existing limitations on their earnings and participation in the economy: 24% because it is their only source of income, 5% can’t get a job, 18% need to supplement income and 24% feel the pressures of higher costs of living. 30% said they became Shopee sellers because of their passion for their business.
Save and Enjoy More with 9.9 Super Shopping Day
To enable Malaysians to stretch their Ringgit even more, Shopee’s 9.9 Super Shopping Day is currently happening till 9 September 2022. More value and joy await shoppers on top of Free Shipping with no minimum spend, daily 95% off deals and a chance to Shop & Win up to RM200,000**.
Malaysians can also look forward to Shopee Live daily exclusive vouchers, worth up to RM6 off with no minimum spend from any livestream on Shopee Live. The Live-exclusive vouchers refresh every day, so users should come back to Shopee livestream daily to claim and use the vouchers on 9.9 Super Shopping Day.
On top of that, users can also participate in the Shopee Live Buy & Win contest to stand a chance to win up to 100,000 Shopee Coins and Gold Bars. This is applicable for purchases made in any livestreams on Shopee Live from 26 August until 9 September.
To top it off, tune in to TV3, Shopee Live or Shopee’s YouTube channel at 9PM on 9 September to get your hands on the best TV deals in town from the Shopee 9.9 Super Show. Full of exciting performances, games and offers, Shopee will be treating Malaysians with Shopee Shake, Vouchers Drop and more during the show for an unforgettable 9.9 Super Shopping Day.
Notes： 1. Survey Methodology* The 2022 “Celebrating the Heart of Malaysia on E-Commerce” survey was conducted by Shopee Marketplace, between 19 July to 17 August 2022. Voluntary feedback was obtained from 2,132 Malaysian sellers and 3,356 Malaysian buyers on the platform.
2. Shopee Malaysia held a virtual press conference on the marketplace survey – ‘Celebrating the Heart of Malaysia on E-Commerce’ on 25 August 2022. To view it in full, please contact pr.my@shopee.com.
Hashtag: #Shopee #MerdekaDay
About Shopee
Shopee is the leading e-commerce platform in Southeast Asia & Taiwan. Shopee promotes an inclusive and sustainable digital ecosystem by enabling businesses to digitalise and grow their online presence, helping more people access and benefit from digital services, and uplifting local communities.
Shopee offers an easy, secure, and engaging experience that is enjoyed by millions of people daily. Shopee is also a key contributor to the region’s digital economy with a firm commitment to helping homegrown brands and entrepreneurs succeed in e-commerce.
Shopee is part of Sea Limited (NYSE: SE), a leading global consumer internet company. Sea’s mission is to better the lives of consumers and small businesses with technology through its three core businesses: Shopee, Garena and SeaMoney.
Meta CEO Mark Zuckerberg has confirmed that Meta’s next virtual reality headset will arrive in October. Zuckerberg made the comments on Joe Rogan’s podcast, indicating the device — almost certainly the headset codenamed “Project Cambria” — will likely launch around the company’s annual Connect event.
“For the next device that’s coming out in October, there’s a few big features,” Zuckerberg said, discussing VR at the beginning of the podcast. He proceeded to describe new social options that would be enabled by eye and facial tracking. “The ability to now have kind of eye contact in virtual reality,” Zuckerberg said as part of the feature list. “Have your face be tracked so that way your avatar — it’s not just this still thing, but if you smile or if you frown or if you pout, or whatever your expression is, have that translate in real time to your avatar.”
That’s consistent with what we know of Project Cambria, which is supposed to have a high-resolution color screen, internal sensors for eye tracking, and sophisticated passthrough augmented reality. As Bloomberg reported last month, leaked code suggests the device could be called the Meta Quest Pro. Whatever it’s ultimately called, Cambria will sit alongside the lower-end Meta Quest — although Meta is reportedly already planning its next generation of both headsets. It’s separate from a still-nascent lineup of Meta augmented reality glasses.
Cambria is supposed to be “significantly” more expensive than the existing Quest, which recently got a price hike to $399. Meta had previously stated that the device will be released sometime this year.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
